FDA meeting prompts new ONS-5010 update, Outlook Therapeutics outlines

FDA meeting prompts new ONS-5010 update, Outlook Therapeutics outlines
Outlook Therapeutics issues FDA update

Outlook Therapeutics has provided a new update following its Type A meeting with the Food and Drug Administration concerning ONS-5010/LYTENAVA, also known as bevacizumab-vikg.

The company is advancing its plans for the investigational therapy, which targets retinal diseases like wet age-related macular degeneration. The latest communication is part of ongoing interactions between Outlook Therapeutics and regulators as it works toward potential approval.

The company’s latest announcement follows a series of regulatory interactions, including its decision to pursue an FDA meeting after receiving a Complete Response Letter for its ophthalmology treatment, as detailed in the article examining Outlook Therapeutics’ response to regulatory feedback. These ongoing developments underscore the firm’s continued efforts to address the challenges facing ONS-5010/LYTENAVA and advance its position within the competitive landscape of retinal disease therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.